Eiger BioPharmaceuticals (NASDAQ:EIGR) appointed Dr. David Apelian as chief operating officer and executive medical officer.Read More
Dr. Jotin Marango and Yasmeen Rahimi have joined the healthcare research team at Roth Capital Partners.Read More
Closely-held Roth Capital Partners named Eric Cheng as managing director, head of healthcare investment banking.Read More
H.C. Wainwright initiated coverage of OSE Immunotherapeutics (ISIN: FR0012127173; Mnémo: OSE) with a “buy” rating and a 12-month price target of €12.00. The stock closed at €6.25 on March 6.Read More
BioTime (NYSE MKT:BTX) has appointed Stephana Patton as general counsel, a newly created position. Reporting in her new role to Adi Mohanty, co-CEO, Dr. Patton will oversee all legal matters at the company.Read More
Kenneth Galbraith, an accomplished life sciences industry veteran, has been appointed a director of Profound Medical (TSX-V:PRN).Read More
3D Signatures (TSX-V:DXD) has appointed Joost van der Mark as its chief business officer, effective Jan. 6.Read More
Joseph Pantginis has joined Rodman & Renshaw in equity research as a managing director covering biotechnology.Read More
Aurinia Pharmaceuticals (NASDAQ:AUPH; TSX:AUP) appointed Lorin Jeffry Randall to its board and chairman of the audit committee.Read More
Stereotaxis (NASDAQ:STXS) has signed definitive agreements for multiple transactions that significantly strengthen its financial position and help accelerate and enhance its strategic market growth initiatives.
The transactions include an equity financing of $24-million, satisfaction in full of outstanding debt to Healthcare Royalty Partners for a payment of $13-million, and the addition to the board of three new directors with significant operational and financial experience in the medical device industry.Read More
Shawn Aspden, a 20-year veteran of the Canadian capital markets, has joined Bloom Burton & Co. as managing director. Mr. Aspden recently served was vice chairman and head of North American institutional equity sales at GMP Securities.
In the role of managing director, Mr. Aspden will expand Bloom Burton’s ability to serve Canadian institutional investors as they consider the important pharmaceutical, biotechnology and healthcare sectors. He will broaden the awareness and distribution of Bloom Burton’s investment banking and advisory capabilities, award-winning equity research, and events such as the firm’s flagship Bloom Burton Healthcare Investor Conference.Read More
Vital Therapies (NASDAQ:VTL) appointed Faheem Hasnain to the board, effective immediately.
Mr. Hasnain served as president, CEO and as a director of Receptos from November 2010 to August 2015, when it was purchased by Celgene for $7.8-billion. He is currently chairman of Tocagen and Sente.Read More
Corey Davis has joined H.C. Wainwright in equity research as a managing director, covering specialty pharmaceuticals.
Dr. Davis has 19 years of sell-side experience, covering specialty pharmaceutical companies, spending most of those years at JP Morgan and Jefferies.Read More